Literature DB >> 14675613

Effects of acute repetitive transcranial magnetic stimulation on dopamine release in the rat dorsolateral striatum.

Manabu Kanno1, Machiko Matsumoto, Hiroko Togashi, Mitsuhiro Yoshioka, Yukio Mano.   

Abstract

Animal studies have shown that descending pathways from the frontal cortex modulate dopamine (DA) release in the striatum. This modulation is thought to be relevant to the pathophysiology of Parkinson's disease. In human, repetitive transcranial magnetic stimulation (rTMS) can result in functional changes in the cortex. The present study intended to clarify the effects of acute rTMS treatment using various stimulation intensities on the extracellular DA concentrations in the rat dorsolateral striatum. The frontal brain of each rat received acute rTMS treatment, which consisted of 500 stimuli from 20 trains in a day. Each train was applied at 25 Hz for 1 s with 1-min intervals between trains. The neurochemical effects of acute rTMS treatment were investigated by determining the extracellular concentrations of DA in the rat dorsolateral striatum using in vivo microdialysis. Acute rTMS treatment of the frontal brain using the stimulation intensity of almost 110% motor threshold (MT) markedly and continuously increased the extracellular DA concentrations in the rat dorsolateral striatum. The present study demonstrates that acute rTMS treatment of the frontal brain affects the DAergic neuronal system in the rat dorsolateral striatum, and may have therapeutic implications for Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14675613     DOI: 10.1016/j.jns.2003.08.013

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  31 in total

1.  Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study.

Authors:  Antonio P Strafella; Ji Hyun Ko; Joshua Grant; Maria Fraraccio; Oury Monchi
Journal:  Eur J Neurosci       Date:  2005-12       Impact factor: 3.386

Review 2.  Transcranial magnetic stimulation in the treatment of substance addiction.

Authors:  David A Gorelick; Abraham Zangen; Mark S George
Journal:  Ann N Y Acad Sci       Date:  2014-07-28       Impact factor: 5.691

3.  Network-Guided Transcranial Magnetic Stimulation for Depression.

Authors:  Marc J Dubin; Conor Liston; Michael A Avissar; Irena Ilieva; Faith M Gunning
Journal:  Curr Behav Neurosci Rep       Date:  2017-02-07

Review 4.  Imaging TMS: antidepressant mechanisms and treatment optimization.

Authors:  Marc Dubin
Journal:  Int Rev Psychiatry       Date:  2017-02-15

Review 5.  Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.

Authors:  David Lindenbach; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2013-10-07       Impact factor: 8.989

Review 6.  Dopaminergic neurotransmission in the human brain: new lessons from perturbation and imaging.

Authors:  Ji Hyun Ko; Antonio P Strafella
Journal:  Neuroscientist       Date:  2011-05-02       Impact factor: 7.519

7.  High- and low-frequency repetitive transcranial magnetic stimulation differentially activates c-Fos and zif268 protein expression in the rat brain.

Authors:  Selcen Aydin-Abidin; Jörn Trippe; Klaus Funke; Ulf T Eysel; Alia Benali
Journal:  Exp Brain Res       Date:  2008-04-02       Impact factor: 1.972

8.  Carbonic anhydrase I, II, and VI, blood plasma, erythrocyte and saliva zinc and copper increase after repetitive transcranial magnetic stimulation.

Authors:  Robert I Henkin; Samuel J Potolicchio; Lucien M Levy; Ramy Moharram; Irina Velicu; Brian M Martin
Journal:  Am J Med Sci       Date:  2010-03       Impact factor: 2.378

Review 9.  Advances in the treatment of depression.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  NeuroRx       Date:  2006-01

10.  rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex.

Authors:  Sang Soo Cho; Antonio P Strafella
Journal:  PLoS One       Date:  2009-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.